Obinutuzumab

Indications & Dose:

Treatment of previously untreated chronic lymphocytic leukaemia in patients for whom full-dose fludarabinebased therapy is unsuitable due to co-morbidities l

• BY INTRAVENOUS INFUSION

Adult: (consult product literature or local protocols)

Contraindications:

Side Effects:

consult product literature.

CONCEPTION AND CONTRACEPTION Use effective contraception during and for 18 months after treatment.

PREGNANCY Avoid unless potential benefit outweighs risk of B-lymphocyte depletion in fetus.

BREAST FEEDING Avoid breast-feeding during and for 18 months after treatment—present in milk in animal studies. 

Cautions:

consult product literature. Hepatitis B infection and reactivation Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking obinutuzumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: